Shares of US-based biotechnology company Sellas Life Sciences extended their spectacular rally on Wednesday, November 18, rising another 5% after soaring nearly 156% in the previous session.
The stock has come under investors' radar following a major breakthrough in a late-stage clinical trial of its experimental cancer vaccine, which demonstrated a significant improvement in survival outcomes among patients with an aggressive form of blood cancer.
The sharp rally came after the company announced positive results from its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine designed to treat acute myeloid leukaemia (AML).
The results marked a significant milestone for the company, with the trial meeting its primary endpoint of overall survival. Sellas said the treatment reduced the risk of death by 41% compared with the best available treatment, with a hazard ratio of 0.59 and a statistically significant p-value of 0.035, as per the company's press release.
The company said that the 126-patient study showed that patients receiving GPS achieved median overall survival of 24 months, compared with 14.7 months among those receiving the best available treatment.